Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A unified approach to risk assessment for fetal aneuploidies

15 Oct 2014

Abstract excerpt

OBJECTIVE: To examine the potential impact of combining measures from cell-free DNA (cfDNA) testing with maternal age and first-trimester biomarkers in screening for fetal trisomies. METHODS: This was a theoretical study using Bayes' theorem to combine the a priori risk for fetal trisomy 21 derived from maternal age with likelihoods from nuchal translucency thickness, serum pregnancy-associated plasma protein-A,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fetal and Pediatric Neurological Disorders
Share to Parvovirus B19 Infection Studies
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25315809
DOI: 10.1002/uog.14694

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 26 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A unified approach to risk assessment for fetal aneuploidiesPMID 25315809Read ↗

Screening for trisomy 18 by maternal age, fetal nuchal translucency, free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

Cell-free fetal DNA testing for fetal aneuploidy and beyond: clinical integration challenges in the US contextSemantic proximity Read ↗

First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testingSemantic proximity Read ↗

Analysis of cell‐free DNA in maternal blood in screening for aneuploidies: updated meta‐analysisSemantic proximity Read ↗

Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

Accuracy of first‐trimester combined test in screening for trisomies 21, 18 and 13Semantic proximity Read ↗

Combined First Trimester Screening and Cell-Free Fetal DNA – “Next Generation Screening”Semantic proximity Read ↗

Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysisSemantic proximity Read ↗

First‐trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell‐free DNA testingSemantic proximity Read ↗

Screening for trisomies 21, 18 and 13 by cell‐free <scp>DNA</scp> analysis of maternal blood at 10–11 weeks' gestation and the combined test at 11–13 weeksSemantic proximity Read ↗

Cell-Free DNA Analysis for Trisomy Risk Assessment in First-Trimester Twin PregnanciesSemantic proximity Read ↗

Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Meta-AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.